Genentech-PDL1 clinical trial

› Forums › General Melanoma Community › Genentech-PDL1 clinical trial

  • This topic is empty.
  • Post
    • November 16, 2012 at 1:14 am
    killmel
    Participant

      Genentech recently updated their trial to increase enrollments & more locations including Europe.

      Increasing the enrollment & adding more locations could be an indication that this drug (MPDL3280A) is getting a good objective response rate

      Study of the Safety and Pharmacokinetics of MPDL3280A Administered Intravenously As a Single Agent to Patients With Locally Advanced or Metastatic Solid Tumors

      http://clinicaltrials.gov/ct2/show/NCT01375842

      Genentech recently updated their trial to increase enrollments & more locations including Europe.

      Increasing the enrollment & adding more locations could be an indication that this drug (MPDL3280A) is getting a good objective response rate

      Study of the Safety and Pharmacokinetics of MPDL3280A Administered Intravenously As a Single Agent to Patients With Locally Advanced or Metastatic Solid Tumors

      http://clinicaltrials.gov/ct2/show/NCT01375842

    • You must be logged in to reply to this topic.
    About the MRF Patient Forum

    The MRF Patient Forum is the oldest and largest online community of people affected by melanoma. It is designed to provide peer support and information to caregivers, patients, family and friends. There is no better place to discuss different parts of your journey with this cancer and find the friends and support resources to make that journey more bearable.

    The information on the forum is open and accessible to everyone. To add a new topic or to post a reply, you must be a registered user. Please note that you will be able to post both topics and replies anonymously even though you are logged in. All posts must abide by MRF posting policies.

    Popular Topics